Curacyte's new approach to shock, Hemoximer, enters Phase III
This article was originally published in Scrip
Executive Summary
Curacyte Health Sciences's nitric oxide scavenger, Hemoximer (pyridoxalated haemoglobin polyoxyethylene, PHP), has entered a Phase III clinical trial in patients with distributive shock.